CA2957396C - Method of determining pik3ca mutational status in a sample - Google Patents
Method of determining pik3ca mutational status in a sample Download PDFInfo
- Publication number
- CA2957396C CA2957396C CA2957396A CA2957396A CA2957396C CA 2957396 C CA2957396 C CA 2957396C CA 2957396 A CA2957396 A CA 2957396A CA 2957396 A CA2957396 A CA 2957396A CA 2957396 C CA2957396 C CA 2957396C
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- dna
- seq
- pik3ca
- mutant allele
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 82
- 230000000869 mutational effect Effects 0.000 title abstract description 20
- 230000035772 mutation Effects 0.000 claims abstract description 207
- 239000000523 sample Substances 0.000 claims abstract description 167
- 108700028369 Alleles Proteins 0.000 claims abstract description 161
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims abstract description 144
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims abstract description 144
- 108020004414 DNA Proteins 0.000 claims abstract description 121
- 201000011510 cancer Diseases 0.000 claims abstract description 78
- 230000000903 blocking effect Effects 0.000 claims abstract description 73
- 238000002844 melting Methods 0.000 claims abstract description 72
- 230000008018 melting Effects 0.000 claims abstract description 72
- 230000003321 amplification Effects 0.000 claims abstract description 26
- 238000004458 analytical method Methods 0.000 claims abstract description 26
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 26
- 239000012472 biological sample Substances 0.000 claims abstract description 17
- 238000003752 polymerase chain reaction Methods 0.000 claims description 69
- 206010006187 Breast cancer Diseases 0.000 claims description 57
- 208000026310 Breast neoplasm Diseases 0.000 claims description 56
- 102000040430 polynucleotide Human genes 0.000 claims description 34
- 108091033319 polynucleotide Proteins 0.000 claims description 34
- 239000002157 polynucleotide Substances 0.000 claims description 34
- 230000000295 complement effect Effects 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 30
- 102000053602 DNA Human genes 0.000 claims description 16
- 108091034117 Oligonucleotide Proteins 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 239000007850 fluorescent dye Substances 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000006820 DNA synthesis Effects 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 230000004568 DNA-binding Effects 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 abstract description 138
- 206010028980 Neoplasm Diseases 0.000 abstract description 103
- 238000001514 detection method Methods 0.000 abstract description 34
- 210000002381 plasma Anatomy 0.000 abstract description 20
- 230000035945 sensitivity Effects 0.000 abstract description 16
- 230000002860 competitive effect Effects 0.000 abstract description 14
- 102200085639 rs104886003 Human genes 0.000 abstract description 14
- 210000005259 peripheral blood Anatomy 0.000 abstract description 11
- 239000011886 peripheral blood Substances 0.000 abstract description 11
- 108700024394 Exon Proteins 0.000 abstract description 10
- 230000004044 response Effects 0.000 abstract description 10
- 102200085789 rs121913279 Human genes 0.000 abstract description 10
- 210000002966 serum Anatomy 0.000 abstract description 6
- 238000011156 evaluation Methods 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 238000011242 molecular targeted therapy Methods 0.000 abstract description 2
- 238000011880 melting curve analysis Methods 0.000 abstract 1
- 239000013615 primer Substances 0.000 description 120
- 206010027476 Metastases Diseases 0.000 description 29
- 230000009401 metastasis Effects 0.000 description 29
- 230000000875 corresponding effect Effects 0.000 description 28
- 238000003556 assay Methods 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 22
- 150000007523 nucleic acids Chemical group 0.000 description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 11
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 102000038030 PI3Ks Human genes 0.000 description 10
- 108091007960 PI3Ks Proteins 0.000 description 10
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000003211 malignant effect Effects 0.000 description 9
- 206010055113 Breast cancer metastatic Diseases 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 238000000137 annealing Methods 0.000 description 7
- 238000007846 asymmetric PCR Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 206010061818 Disease progression Diseases 0.000 description 6
- 206010061819 Disease recurrence Diseases 0.000 description 6
- 238000007844 allele-specific PCR Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000002987 primer (paints) Substances 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 238000002626 targeted therapy Methods 0.000 description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 208000035269 cancer or benign tumor Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000007730 Akt signaling Effects 0.000 description 3
- 101150063858 Pik3ca gene Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100026203 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) neg-1 gene Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000011226 adjuvant chemotherapy Methods 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007847 digital PCR Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 208000026037 malignant tumor of neck Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 230000006685 micro-environmental stress Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000011353 adjuvant radiotherapy Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000594 epithelial cell of lung Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/186—Modifications characterised by incorporating a non-extendable or blocking moiety
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2527/00—Reactions demanding special reaction conditions
- C12Q2527/107—Temperature of melting, i.e. Tm
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462034231P | 2014-08-07 | 2014-08-07 | |
| US62/034,231 | 2014-08-07 | ||
| PCT/GR2015/000036 WO2016020710A1 (en) | 2014-08-07 | 2015-07-28 | Method of determining pik3ca mutational status in a sample |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2957396A1 CA2957396A1 (en) | 2016-02-11 |
| CA2957396C true CA2957396C (en) | 2021-03-09 |
Family
ID=53938365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2957396A Active CA2957396C (en) | 2014-08-07 | 2015-07-28 | Method of determining pik3ca mutational status in a sample |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11279979B2 (OSRAM) |
| EP (1) | EP3198026B1 (OSRAM) |
| JP (1) | JP6770957B2 (OSRAM) |
| CN (1) | CN106715723B (OSRAM) |
| CA (1) | CA2957396C (OSRAM) |
| CY (1) | CY1122647T1 (OSRAM) |
| DK (1) | DK3198026T3 (OSRAM) |
| ES (1) | ES2764423T3 (OSRAM) |
| HR (1) | HRP20192353T1 (OSRAM) |
| HU (1) | HUE047958T2 (OSRAM) |
| IL (1) | IL250392B (OSRAM) |
| LT (1) | LT3198026T (OSRAM) |
| PL (1) | PL3198026T3 (OSRAM) |
| PT (1) | PT3198026T (OSRAM) |
| RS (1) | RS59710B1 (OSRAM) |
| SI (1) | SI3198026T1 (OSRAM) |
| SM (1) | SMT202000005T1 (OSRAM) |
| WO (1) | WO2016020710A1 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3023788T3 (da) | 2010-05-14 | 2020-04-27 | Massachusetts Gen Hospital | Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer |
| WO2015039024A1 (en) | 2013-09-16 | 2015-03-19 | Oregon Health & Science University | Bioabsorbable clips and applicator for tissue closure |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| CA2934073A1 (en) | 2013-12-20 | 2015-06-25 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| US9883866B2 (en) | 2014-11-03 | 2018-02-06 | Oregon Health & Science University | Clips and applicator for tissue closure |
| EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
| ES3049406T3 (en) * | 2014-12-19 | 2025-12-16 | Broad Inst Inc | Methods for profiling the t-cell-receptor repertoire |
| PE20180670A1 (es) | 2015-05-20 | 2018-04-19 | Broad Inst Inc | Neoantigenos compartidos |
| US10870891B2 (en) | 2017-01-05 | 2020-12-22 | Biodesix, Inc. | Diagnostic test system for specific, sensitive and reproducible detection of circulating nucleic acids in whole blood |
| EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| CN118370809A (zh) | 2017-04-03 | 2024-07-23 | 百欧恩泰美国公司 | 蛋白质抗原及其用途 |
| CN107287309A (zh) * | 2017-07-06 | 2017-10-24 | 罗保君 | 一种血液循环肿瘤dna点突变检测方法 |
| JP6603827B2 (ja) * | 2017-07-26 | 2019-11-06 | 積水メディカル株式会社 | 変異遺伝子検出方法 |
| CN109295175A (zh) * | 2017-09-08 | 2019-02-01 | 广州健天基因技术有限公司 | 用于检测人胃肠道间质瘤c-kit基因v559a突变的引物、检测方法及试剂盒 |
| CN109306374A (zh) * | 2017-09-08 | 2019-02-05 | 广州健天基因技术有限公司 | 用于检测人类pik3ca基因e545k突变的引物、检测方法及试剂盒 |
| JP7306618B2 (ja) * | 2017-09-26 | 2023-07-11 | 東ソー株式会社 | がんの転移形成能に関与する因子および前記因子を用いたがん患者の予後予測方法 |
| WO2019126186A1 (en) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
| CN107937490A (zh) * | 2018-01-15 | 2018-04-20 | 福建农林大学 | 一种非对称pcr的试纸条检测植物病原菌的方法及试剂盒 |
| WO2019155050A1 (en) * | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Method of predicting response to therapy by assessing tumor genetic heterogeneity |
| JP7534962B2 (ja) | 2018-06-19 | 2024-08-15 | ビオンテック ユーエス インコーポレイテッド | ネオ抗原およびその使用 |
| CN109666747A (zh) * | 2019-02-20 | 2019-04-23 | 天津脉络医学检验有限公司 | 一种引物探针组合物及其应用 |
| US11812966B2 (en) | 2020-04-24 | 2023-11-14 | NeuraMedica Inc. | Clips, appliers, and cartridges |
| CN113930500B (zh) * | 2020-07-13 | 2024-11-19 | 铭炽生物科技(上海)有限公司 | 人pik3ca基因突变的数字pcr检测方法及应用 |
| CN112951325B (zh) * | 2021-02-18 | 2023-04-21 | 北京吉因加医学检验实验室有限公司 | 一种用于癌症检测的探针组合的设计方法及其应用 |
| CN113063835B (zh) * | 2021-03-19 | 2022-08-02 | 中山大学 | 一种基于元素标记-电感耦合等离子体质谱检测策略的cfDNA分析方法及其应用 |
| WO2023025218A1 (zh) * | 2021-08-25 | 2023-03-02 | 南京金斯瑞生物科技有限公司 | 一种用于检测单碱基突变的引物组和基因芯片方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3296407T1 (sl) | 2004-03-02 | 2019-09-30 | The Johns Hopkins University | Mutacije gena PIK3CA pri rakih pri ljudeh |
| SG10201506658TA (en) * | 2007-02-26 | 2015-09-29 | Wayne John Cancer Inst | Utility of b-raf dna mutation in diagnosis and treatment of cancer |
| US8071338B2 (en) * | 2007-08-08 | 2011-12-06 | Roche Molecular Systems, Inc. | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity |
| GB2453173A (en) * | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| US20100041048A1 (en) * | 2008-07-31 | 2010-02-18 | The Johns Hopkins University | Circulating Mutant DNA to Assess Tumor Dynamics |
| CN101445832B (zh) * | 2008-12-23 | 2011-09-14 | 广州益善生物技术有限公司 | Pik3ca基因突变的检测探针、液相芯片及其检测方法 |
| CN102234685B (zh) * | 2010-04-23 | 2014-08-27 | 益善生物技术股份有限公司 | 一种pik3ca基因突变检测液相芯片 |
| WO2012075231A1 (en) * | 2010-12-03 | 2012-06-07 | Brandeis University | Methods and kits for detecting nucleic acid mutants in wild-type populations |
| CN102533958A (zh) | 2010-12-28 | 2012-07-04 | 苏州科贝生物技术有限公司 | 一种检测人pik3ca基因突变的方法和试剂盒 |
| EP2663652B1 (en) * | 2011-01-11 | 2018-11-14 | Roche Diagniostics GmbH | High resolution melting analysis as a prescreening tool |
| WO2012131092A2 (en) * | 2011-03-31 | 2012-10-04 | Signature Diagnostics Ag | Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages |
| CN103635593B (zh) * | 2011-05-04 | 2018-03-20 | 生物概念股份有限公司 | 用于检测核酸序列变体的方法 |
| SG2014010276A (en) | 2011-08-18 | 2014-03-28 | Nestec Sa | Compositions and methods for detecting allelic variants |
| JP2013081450A (ja) | 2011-09-27 | 2013-05-09 | Arkray Inc | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用試薬キット |
| US11261494B2 (en) * | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
| EP2711432A1 (en) * | 2012-09-21 | 2014-03-26 | Genomica S.A.U. | Method for detection of BRAF and PI3K mutations |
| EP3666903B1 (en) * | 2013-08-12 | 2025-12-31 | Bio-Rad Laboratories, Inc. | AMPLIFICATION REPORTER GENE CONTAINING OLIGOMERS WITH BASIC PAIRINGS |
-
2015
- 2015-07-28 PT PT157537457T patent/PT3198026T/pt unknown
- 2015-07-28 CN CN201580052321.9A patent/CN106715723B/zh active Active
- 2015-07-28 RS RS20191668A patent/RS59710B1/sr unknown
- 2015-07-28 HU HUE15753745A patent/HUE047958T2/hu unknown
- 2015-07-28 WO PCT/GR2015/000036 patent/WO2016020710A1/en not_active Ceased
- 2015-07-28 HR HRP20192353TT patent/HRP20192353T1/hr unknown
- 2015-07-28 PL PL15753745T patent/PL3198026T3/pl unknown
- 2015-07-28 US US15/501,457 patent/US11279979B2/en active Active
- 2015-07-28 DK DK15753745.7T patent/DK3198026T3/da active
- 2015-07-28 CA CA2957396A patent/CA2957396C/en active Active
- 2015-07-28 ES ES15753745T patent/ES2764423T3/es active Active
- 2015-07-28 EP EP15753745.7A patent/EP3198026B1/en active Active
- 2015-07-28 SI SI201531052T patent/SI3198026T1/sl unknown
- 2015-07-28 JP JP2017526770A patent/JP6770957B2/ja active Active
- 2015-07-28 LT LTEP15753745.7T patent/LT3198026T/lt unknown
- 2015-07-28 SM SM20200005T patent/SMT202000005T1/it unknown
-
2017
- 2017-02-01 IL IL250392A patent/IL250392B/en active IP Right Grant
-
2019
- 2019-12-30 CY CY20191101363T patent/CY1122647T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3198026A1 (en) | 2017-08-02 |
| CY1122647T1 (el) | 2021-03-12 |
| EP3198026B1 (en) | 2019-10-09 |
| JP6770957B2 (ja) | 2020-10-21 |
| SMT202000005T1 (it) | 2020-03-13 |
| US11279979B2 (en) | 2022-03-22 |
| PL3198026T3 (pl) | 2020-05-18 |
| IL250392B (en) | 2020-03-31 |
| ES2764423T3 (es) | 2020-06-03 |
| LT3198026T (lt) | 2020-01-27 |
| CN106715723A (zh) | 2017-05-24 |
| HRP20192353T1 (hr) | 2020-03-20 |
| CN106715723B (zh) | 2021-03-30 |
| US20170233821A1 (en) | 2017-08-17 |
| DK3198026T3 (da) | 2020-01-20 |
| WO2016020710A1 (en) | 2016-02-11 |
| JP2017523810A (ja) | 2017-08-24 |
| HUE047958T2 (hu) | 2020-05-28 |
| SI3198026T1 (sl) | 2020-02-28 |
| CA2957396A1 (en) | 2016-02-11 |
| RS59710B1 (sr) | 2020-01-31 |
| PT3198026T (pt) | 2020-01-16 |
| IL250392A0 (en) | 2017-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2957396C (en) | Method of determining pik3ca mutational status in a sample | |
| AU2022228167B2 (en) | Methods and materials for assessing loss of heterozygosity | |
| US12270081B2 (en) | Method for quantification of PD-L1 expression | |
| Voutsina et al. | Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer | |
| Polivka Jr et al. | Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? | |
| JP6285009B2 (ja) | 前立腺ガンの予後の検知及び判定のための組成物及び該検知及び判定方法 | |
| KR20240104202A (ko) | 순환 종양 핵산 분자의 다중모드 분석 | |
| WO2012131092A2 (en) | Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages | |
| US12391985B2 (en) | Method of determining PIK3CA mutational status in a sample | |
| US20250129428A1 (en) | Methods and materials for predicting the progression of prostate cancer and treating same | |
| HK1241934A1 (en) | Method of determining pik3ca mutational status in a sample | |
| HK1241934B (en) | Method of determining pik3ca mutational status in a sample | |
| CN106119398B (zh) | 预测乳腺癌患者对吡咯替尼治疗反应性的生物标记物 | |
| HK40120571A (en) | Methods and materials for assessing loss of heterozygosity | |
| JP2014527816A (ja) | 初期卵巣がんの検出マーカーとしての精子タンパク質 | |
| Richter-Pechańska | A novel approach to develop predictive biomarkers: prediction of response to anti-EGFR therapy in a large panel of patient-derived colorectal cancer xenograft models | |
| Pechanska | A novel approach to develop predictive biomarkers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200115 |